Article Text

Download PDFPDF

POS1380 LONG-TERM EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH TRAPS (TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED PERIODIC SYNDROME) - INTERIM ANALYSIS OF THE RELIANCE REGISTRY
Free
  1. N. Blank1,
  2. J. Henes2,
  3. T. Kallinich3,
  4. P. Oommen4,
  5. C. Schuetz5,
  6. M. Borte6,
  7. J. Weber-Arden7,
  8. J. B. Kuemmerle-Deschner8
  1. 1University Hospital Heidelberg, Rheumatology, Heidelberg, Germany
  2. 2University Hospital Tuebingen, Department of Internal Medicine II, Rheumatology, Tuebingen, Germany
  3. 3Charité University Medicine Berlin, Department of Pediatrics, Division of Pulmonology, Immunology and Critical Care Medicine, Berlin, Germany
  4. 4Heinrich-Heine-University Düsseldorf, Clinic of Pediatric Hematology, Oncology and Clinical Immunology, Duesseldorf, Germany
  5. 5Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Pediatrics, Dresden, Germany
  6. 6Hospital St. Georg gGmbH Leipzig, ImmunoDeficiencyCenter Leipzig (IDCL), Leipzig, Germany
  7. 7Novartis Pharma GmbH, Novartis Pharma GmbH, Nuernberg, Germany
  8. 8University Hospital Tuebingen, Department of Pediatrics, Division of Pediatric Rheumatology, Tuebingen, Germany

Abstract

Background: Tumor necrosis factor receptor-associated periodic syndrome (TRAPS) is a rare autoinflammatory condition characterized by severe systemic and organ inflammation. In a phase 3 pivotal trial (CLUSTER study), TRAPS patients have been successfully treated with the interleukin-1β inhibitor canakinumab. 45% of patients reached clinical remission after 16 weeks (primary endpoint)1. Canakinumab has been approved and applied for the treatment of TRAPS patients since 20172.

Objectives: The present study explores the long-term efficacy and safety of canakinumab under routine clinical practice conditions in pediatric (age ≥2 years) and adult TRAPS patients.

Methods: RELIANCE is a prospective, non-interventional, multi-center, observational study based in Germany with a 3-year follow-up period. Patients with clinically confirmed diagnoses of TRAPS, CAPS, FMF or HIDS/MKD who routinely receive canakinumab are enrolled in order to evaluate efficacy and safety of canakinumab under standard clinical practice conditions. Disease activity and remission by physician assessment, disease activity and fatigue by patient assessment, days absent from school/work due to study indication, inflammatory markers, and AIDAI (Auto-Inflammatory Diseases Activity Index) score were assessed at baseline and at 6-monthly intervals.

Results: The interim analysis of TRAPS patients enrolled by December 2020 includes baseline (N=16, including 1 patient with atypical TRAPS) and preliminary 18-month data. Mean age in this cohort was 23 years (3−43 years) and the median duration of prior CAN treatment was 1.0 year (0−4 years).

Physician assessment indicated 60-80% remission and laboratory parameters were within normal range. Disease control by patient assessment showed no major changes regarding the analyzed parameters (Table 1, Figure 1). Of the three serious adverse events reported none was classified as drug-related.

Conclusion: Preliminary analysis of 18 month interim data of TRAPS patients treated with CAN available from the RELIANCE study indicate stable efficacy and safety of CAN long-term treatment.

References: [1]De Benedetti F, et al. Canakinumab for the treatment of autoinflammatory recurrent fever syndromes. N Engl J Med 2018;378:1908–19.

[2]Ilaris, INN-canakinumab (europa.eu)

Table 1.

Baseline characteristics and interim analysis data of patients with TRAPS

Disclosure of Interests: Norbert Blank Consultant of: Novartis, Sobi, Lilly, Pfizer, Abbvie, BMS, MSD, Actelion, UCB, Boehringer-Ingelheim, Roche, Grant/research support from: Novartis, Sobi, Jörg Henes Consultant of: Novartis, AbbVie, Sobi, Roche, Janssen, Boehringer-Ingelheim, Grant/research support from: Novartis, Roche, Tilmann Kallinich Consultant of: Sobi, Novartis, Roche, Grant/research support from: Novartis, Prasad Oommen Grant/research support from: Novartis, Catharina Schuetz: None declared, Michael Borte Grant/research support from: Pfizer, Shire, Julia Weber-Arden Employee of: Novartis, J. B. Kuemmerle-Deschner Consultant of: Novartis, AbbVie, Sobi, Grant/research support from: Novartis, AbbVie, Sobi

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.